Clinical evaluation of measurement of Toll-like receptor 2 and CD64 receptor on peripheral blood mononuclear cell in pneumonia patients

Clinical evaluation of measurement of Toll-like receptor 2 and CD64 receptor on peripheral blood mononuclear cell in pneumonia patients - Clinical evaluation Toll-like receptor 2 and CD64 receptor measurement on PBMC in pneumonia patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005512

Enrollment

120

Registered

2011-04-27

Start date

2010-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired pneumonia, Hospital-acquired pneumonia, Healthcare-associated pneumonia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. New infiltrates on chest X-ray films including CT and fulfill at least one of following two conditions; 1) inflammatory findings (1)Fever; over 37 C (2)Increase of WBC (3)Positive CRP 2)clinical symptoms (1)Cough (2)Purulent sputum or deterioration of sputum (3)Abnormal findings in auscultation and percussion of chest (4)Deterioration of dyspnea, tachypnea or increase of respiratory rate (5)Hypoxia 2. Patients who are agreed to participate to this study with informed consents 3. Both of outpatient and inpatient can participate to this study

Exclusion criteria

Exclusion criteria: The following patients were excluded from the study: (1) patients received any antibiotics prior to this study, (2) patients received immunosuppressive agents, (3) patients with taking steroids (more than 10mg/day as predonisolone), (4) patients who were not considered as participant by attending physician

Design outcomes

Primary

Measure	Time frame
(1) Evaluation of relation between severity of pneumonia and expression of TLR2 and CD64 on PBMC of pneumonia patient. Severity of pneumonia is defined by A-DROP, PSI, I-ROAD, and their combinations. (2) Evaluation of relation between common inflammatory markers and expression of TLR2 and CD64 on PBMC of pneumonia patient. Common inflammatory markers are C-reactive proteins, white blood cell count, cytokines and procalcitonin. (3) Evaluation of relation between patient outcome and prognosis and expression of TLR2 and CD64 on PBMC of pneumonia patient. (4) Evaluation of relation between causative agents and expression of TLR2 and CD64 on PBMC of pneumonia patient.	—

Measure

Time frame

(1) Evaluation of relation between severity of pneumonia and expression of TLR2 and CD64 on PBMC of pneumonia patient. Severity of pneumonia is defined by A-DROP, PSI, I-ROAD, and their combinations. (2) Evaluation of relation between common inflammatory markers and expression of TLR2 and CD64 on PBMC of pneumonia patient. Common inflammatory markers are C-reactive proteins, white blood cell count, cytokines and procalcitonin. (3) Evaluation of relation between patient outcome and prognosis and expression of TLR2 and CD64 on PBMC of pneumonia patient. (4) Evaluation of relation between causative agents and expression of TLR2 and CD64 on PBMC of pneumonia patient.

—

Countries

Japan

Contacts

Public ContactKoichi Izumikawa

Nagasaki evaluation organization for clinical interventions office

shinkin@peath.co.jp

Outcome results